The news comes alongside the U.S. Department of Defense’s announcement of $200 million contracts awarded to xAI, Anthropic, Google and OpenAI for AI implementation.

The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.

Developing an AI platform internally can be more cost-effective and manageable, said Ryan Sadeghian, chief medical information officer at the University of Toledo, at HIMSS AI Forum.

The new firm, TandemAI will offer partners an expanded range of methods and workflows for small-molecule and peptide drug ...